Explaining multiple sclerosis
(Source: MayoClinic.com Full Feed)
Source: MayoClinic.com Full Feed - November 4, 2023 Category: Consumer Health News Source Type: news
Central Vein Sign as an Imaging Biomarker of Multiple Sclerosis
(MedPage Today) -- MedPage Today brought together three expert leaders for a virtual roundtable discussion on the joint meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the American Committee for... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - November 3, 2023 Category: Neurology Source Type: news
No Increase in MS Disease Activity Due to COVID-19 No Increase in MS Disease Activity Due to COVID-19
COVID-19 has no impact on disease activity, progression, or cognitive performance in patients with multiple sclerosis.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - November 3, 2023 Category: Infectious Diseases Tags: Neurology & Neurosurgery News Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces EMBARK trial in Duchenne muscular dystrophy (DMD) did not reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints
This study is ongoing.Study 301 (EMBARK), a Phase 3 global, randomised, double-blinded and placebo-controlled study of Elevidys in ambulatory Duchenne patients aged 4-<8 years old.The ENVOL trial (Study 302) a Phase 2 study in children with Duchenne. The study aims to enrol 21 participants who are under 4 years of age, including newborns. Not yet started.The ENVISION trial (Study 303), a Phase 3 study in older ambulatory/non-ambulatory patients which is now recruiting.The EXPEDITION long-term (5 year) follow up study (Study 305) of participants who have received Elevidys in a previous clinical study, which is not yet re...
Source: Roche Media News - October 31, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces EMBARK trial in Duchenne muscular dystrophy (DMD) did not reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints
This study is ongoing.Study 301 (EMBARK), a Phase 3 global, randomised, double-blinded and placebo-controlled study of Elevidys in ambulatory Duchenne patients aged 4-<8 years old.The ENVOL trial (Study 302) a Phase 2 study in children with Duchenne. The study aims to enrol 21 participants who are under 4 years of age, including newborns. Not yet started.The ENVISION trial (Study 303), a Phase 3 study in older ambulatory/non-ambulatory patients which is now recruiting.The EXPEDITION long-term (5 year) follow up study (Study 305) of participants who have received Elevidys in a previous clinical study, which is not yet re...
Source: Roche Investor Update - October 31, 2023 Category: Pharmaceuticals Source Type: news
Emerging Biomarkers of Multiple Sclerosis in Blood and CSF
(MedPage Today) -- MedPage Today brought together three expert leaders for a virtual roundtable discussion on the joint meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the American Committee for... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - October 27, 2023 Category: Neurology Source Type: news
' Frame Running' May Help Boost Physical Activity in MS'Frame Running' May Help Boost Physical Activity in MS
People with multiple sclerosis and moderate-to-severe walking disability could engage in physical activity and improve their physical function with an adapted running frame, suggests new research.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 23, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
S1P Receptor Modulator May Boost Cognitive Processing Speed in Early MS
(MedPage Today) -- Treatment with ozanimod (Zeposia) led to clinically meaningful improvement in cognitive processing speed among people with early relapsing multiple sclerosis (RMS), an ad hoc interim analysis of the phase IIIb ENLIGHTEN trial... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - October 19, 2023 Category: Neurology Source Type: news
‘The Sopranos’’ Jamie-Lynn Sigler Opens Up About Multiple Sclerosis
At 20, Jamie-Lynn Sigler was starring in the biggest show on TV. 'The Sopranos'' star was on top of the world —until she wasn't. Sigler shares her multiple sclerosis story (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 19, 2023 Category: Pharmaceuticals Authors: Lipi Roy, MD, MPH, Contributor Tags: Healthcare /healthcare Innovation /innovation Business /business Hollywood & Entertainment /hollywood-entertainment pharma standard Source Type: news
‘Sopranos’ Star Jamie-Lynn Sigler Opens Up About Multiple Sclerosis
At 20, Jamie-Lynn Sigler was starring in the biggest show on TV. 'The Sopranos'' star was on top of the world —until she wasn't. Sigler shares her multiple sclerosis story (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 19, 2023 Category: Pharmaceuticals Authors: Lipi Roy, MD, MPH, Contributor Tags: Healthcare /healthcare Innovation /innovation Business /business Hollywood & Entertainment /hollywood-entertainment pharma standard Source Type: news
BTK Inhibitor Reduces Brain Lesions in Relapsing MS
(MedPage Today) -- MILAN -- Investigational fenebrutinib reduced brain lesions in relapsing multiple sclerosis (MS) patients and showed evidence of central nervous system (CNS) penetration, data from the phase II FENopta study showed.
Compared... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - October 19, 2023 Category: Neurology Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Basel, 19 October 2023Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecen...
Source: Roche Media News - October 19, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecentriqPositive phase III...
Source: Roche Investor Update - October 19, 2023 Category: Pharmaceuticals Source Type: news
Neurofilament Light Predicts MS Worsening in Silent Progression
(MedPage Today) -- Neuroaxonal pathology occurred in advance of -- not coincident with -- clinical worsening in multiple sclerosis (MS), particularly in patients with "silent progression" or progression independent of relapse activity (PIRA... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - October 17, 2023 Category: Neurology Source Type: news
MS-Specific Internet-Based Therapy Program Can Cut Depressive Symptoms
TUESDAY, Oct. 17, 2023 -- A multiple sclerosis (MS)-specific internet-based cognitive behavioral therapy (iCBT) program can reduce depressive symptoms among patients with MS, according to a study published in the October issue of The Lancet Digital... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 17, 2023 Category: Pharmaceuticals Source Type: news
